Filing summary
Registrant and period: The supplied filing is Cara Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2014, filed November 10, 2014. This does not match the request metadata naming Tvardi Therapeutics, Inc. Figures below are in U.S. dollars; financial statement amounts are in millions unless noted.
Business context and reporting period
Cara was a clinical-stage biopharmaceutical company developing CR845-based treatments for pain and pruritus. It had no products for sale; substantially all revenue came from license and collaboration arrangements. Its lead candidate, intravenous (I.V.) CR845, was being advanced for acute pain, while Oral CR845 and I.V. CR845 for uremic pruritus were also in development.
Financial results and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $1.125 | $1.018 | $2.263 | $10.991 |
| Research and development expense | $6.208 | $3.764 | $11.609 | $6.707 |
| General and administrative expense | $1.520 | $0.795 | $4.390 | $2.416 |
| Operating loss (income) | $(6.603) | $(3.541) | $(13.736) | $1.868 |
| Net loss | $(6.545) | $(4.575) | $(13.573) | $(1.870) |
| Loss per share, basic and diluted | $(0.29) | $(1.07) | $(0.67) | $(0.24) |
| Operating cash flow | Not separately presented for the quarter | $(11.818) | $7.893 |
- At September 30, 2014, cash and cash equivalents were $58.393 million, restricted cash was $0.700 million, total assets were $62.372 million, and current liabilities were $6.093 million. The current ratio was approximately 9.8x.
- For the first nine months, investing cash outflow was $0.027 million and financing cash inflow was $57.881 million, primarily reflecting the IPO. Cash increased $46.036 million from year-end 2013.
- The balance sheet reported no outstanding convertible preferred stock at quarter-end. No debt balance was reported; prior convertible notes had been converted or repaid before 2014.
- Gross margin is not meaningfully presented: the company had no product sales and reported research and development and general and administrative expenses rather than a product cost-of-sales line.
Material changes versus the prior comparable period
- Nine-month revenue declined $8.728 million year over year, chiefly because 2013 included $9.637 million of license-fee revenue from the Maruishi agreement; 2014 included $0.302 million of license fees. Collaborative revenue increased to $1.961 million from $1.354 million.
- Nine-month R&D expense rose $4.902 million, reflecting expanded clinical work and manufacturing, including Oral CR845, the I.V. CR845 abuse-liability trial, and the uremic-pruritus study. G&A rose $1.974 million, including public-company costs, higher compensation, and stock-based compensation.
- Nine-month operating results shifted from income of $1.868 million to a loss of $13.736 million; net loss widened to $13.573 million. The prior-year period included significant license revenue and noncash interest expense on convertible notes.
- In February 2014, Cara completed its IPO, issuing 5.75 million shares at $11 per share. Preferred stock converted into common stock at the IPO; common shares outstanding increased from 4.288 million at December 31, 2013 to 22.779 million at September 30, 2014.
- Q3 net loss widened by $1.970 million year over year, as higher operating expenses outweighed modest revenue growth; lower interest expense partly offset the increase.
Outlook, management commentary, and risks
- Management expected September 30 cash to fund operations and capital requirements for at least 18 months, excluding potential collaboration milestones. It also cautioned that clinical timing and costs could cause cash to be used sooner than expected.
- Management planned to seek an FDA End-of-Phase-2 meeting before year-end 2014 and anticipated starting I.V. CR845 Phase 3 trials in early 2015, subject to completion of manufacturing and chemistry requirements. It expected Oral CR845 tablet Phase 1 top-line data in Q4 2014 and uremic-pruritus dose-ranging and safety data before year-end, with efficacy results in the first half of 2015.
- Subsequent to quarter-end, Cara reported that an October 2014 I.V. CR845 human abuse-liability trial met its primary endpoint, with lower drug-liking scores than pentazocine; the filing described this as supporting potential for a Schedule V or non-scheduled classification, subject to regulatory outcomes.
- The company expected significant future operating losses and higher development costs, particularly as it pursued Phase 3 trials. It had an accumulated deficit of $76.029 million and relied on financing and collaboration income; additional financing might be needed and could be unavailable or dilutive.
- Key risks include clinical-trial results and enrollment, regulatory approval, manufacturing, intellectual-property protection, competition, market acceptance and reimbursement, dependence on collaborators and key personnel, and the ability to raise capital. The company reported no material legal proceedings, no off-balance-sheet arrangements, and no material changes to previously disclosed risk factors.
- Contractual commitments totaled $6.800 million, comprising operating leases of $2.754 million and executive employment agreements of $4.046 million. Management said disclosure controls were effective as of September 30, 2014.
Important facts for investors to verify
- Confirm the intended issuer: the filing identifies Cara Therapeutics, Inc., not Tvardi Therapeutics, Inc.
- Track actual FDA discussions, Phase 3 start dates, trial costs, and subsequent clinical results for I.V. CR845; verify the reported October abuse-liability results and any regulatory scheduling conclusions.
- Monitor cash burn against the stated 18-month runway, including changes in clinical spending and any financing needs.
- Review the timing and accounting of Maruishi deferred revenue, remaining milestone opportunities, and the conditional nature of future CKD and Maruishi milestones and royalties.
- Assess dilution from the post-IPO share count and outstanding options; the filing reported 964,360 options outstanding at September 30, 2014.